Vitamin D and autoimmune thyroid diseases - Core

Cellular & Molecular Immunology (2011) 8, 243–247 ß 2011 CSI and USTC. All rights reserved 1672-7681/11 $32.00 www.nature.com/cmi

RESEARCH ARTICLE

Vitamin D and autoimmune thyroid diseases Shaye Kivity1,2,3,7, Nancy Agmon-Levin1,4,7, Michael Zisappl1, Yinon Shapira1, Endre V Nagy5, Katalin Danko´5, Zoltan Szekanecz5, Pnina Langevitz3 and Yehuda Shoenfeld1,4,6 The role of vitamin D as an immune modulator has been emphasized in recent years, and low levels of the hormone were observed in several autoimmune diseases including multiple sclerosis and systemic lupus erythematosus. Vitamin D mediates its effect though binding to vitamin D receptor (VDR), and activation of VDR-responsive genes. While VDR gene polymorphism was found to associate with autoimmune thyroid diseases (AITDs), few studies examined levels of vitamin D in these patients and those that did yielded conflicting results. We therefore undertook to evaluate the levels of vitamin D in patients with AITDs compared to patients with non-AITDs and healthy controls. Serum vitamin D (25-OH) levels were measured in 50 patients with AITDs, 42 patients with non-AITDs and 98 healthy subjects, utilizing the LIAISON chemiluminescence immunoassay (DiaSorin, Saluggia, Italy). Vitamin D deficiency was designated at levels lower than 10 ng/ml. Antithyroid antibodies, thyroid functions and demographic parameters were evaluated in all patients. The prevalence of vitamin D deficiency was significantly higher in patients with AITDs compared with healthy individuals (72% versus 30.6%; P,0.001), as well as in patients with Hashimoto’s thyroiditis compared to patients with non-AITDs (79% versus 52%; P,0.05). Vitamin D deficiency also correlated to the presence of antithyroid antibodies (P50.01) and abnormal thyroid function tests (P50.059). Significantly low levels of vitamin D were documented in patients with AITDs that were related to the presence of anti thyroid antibodies and abnormal thyroid function tests, suggesting the involvement of vitamin D in the pathogenesis of AITDs and the advisability of supplementation. Cellular & Molecular Immunology (2011) 8, 243–247; doi:10.1038/cmi.2010.73; published online 31 January 2011 Keywords: autoantibodies; autoimmune thyroid disease; Graves’ disease; Hashimoto’s thyroiditis; vitamin D

INTRODUCTION Vitamin D deficiency has become a common problem in the general population, and has been linked to an increase in cardiovascular diseases,1 cancer2 and infections.3 The low levels of vitamin D have been attributed to reduced sun exposure and physical activity as well as obesity. Vitamin D supplement appears to reduce the incidence of these morbidities and may reduce all-cause mortality.4,5 Deficiency of vitamin D was also found to correlate with an increased incidence of autoimmune diseases, including type I diabetes mellitus (T1DM),6 rheumatoid arthritis7 and systemic lupus erythematosus.8–10 This observation was linked to the latitude differences found in several autoimmune diseases.11,12 For example, the geographic distribution of multiple sclerosis (MS) was inversely correlated with vitamin D status and areas of sunny weather;13 the incidence of T1DM was positively correlated with north–south latitude, less sunshine exposure and season of birth;14 and vitamin D supplements in early life was inversely correlated with risk of T1DM later on.15 In animal models of autoimmune diseases, vitamin D was shown to reduce severity of symptoms and decrease the Th1 response in experimental autoimmune encephalomyelitis and collagen-induced arthritis, 1

and prevent clinical diabetes and pancreatic lesions in the non-obese diabetic mice model.16 Treatment with vitamin D proved beneficial in the management of autoimmune disorders in humans, by diminishing exacerbations of MS, reducing pain and C-reactive protein levels in rheumatoid arthritis and psoriatic arthritis, and preventing the development of MS or T1DM when given prophylactically.6,7,17–21 Animal models have also demonstrated a role for vitamin D in autoimmune thyroid diseases (AITDs): vitamin D supplementation, in addition to cyclosporine, effectively prevented the induction of experimental autoimmune thyroiditis,22 and vitamin D-deficient BALB/c mice developed persistent hyperthyroidism.23 Few studies have examined the impact of vitamin D deficiency on the incidence of AITDs in humans and those that did yielded conflicting results. Vitamin D levels were found to be lower in patients with AITDs than in healthy volunteers in one study,24 and in Graves’ disease patients when compared to patients with non-AITDs (e.g., toxic nodular goiter).25 In contrast, a recent study from India found only a weak connection between low vitamin D levels and AITDs.26. In view of these conflicting results and the dearth of published studies, we examined levels of vitamin D among patients with thyroid diseases,

The Zabludovicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medicine ‘A & C’, Sheba Medical Center, Tel-Hashomer, Israel; 3Rheumatic Disease Unit, Sheba Medical Center, Tel-Hashomer, Israel; 4Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel; 5University of Debrecen. Medical and Health Science Center, Debrecen, Hungary and 6Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune Diseases, Tel Aviv University, Tel Aviv, Israel 7 These authors contributed equally to this work. Correspondence: Y Shoenfeld, Department of Medicine ‘B’, The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel. E-mail: [email protected] Received 1 December 2010; accepted 2 December 2010 2

Vitamin D levels in autoimmune thyroid diseases S Kivity et al 244

and the correlation between vitamin D deficiency and AITDs (Hashimoto’s thyroiditis and Graves’ disease), thyroid function, thyroid autoantibodies and demographic characteristics. MATERIALS AND METHODS Study population Serum samples were collected from 92 patients followed by the outpatient endocrinology clinic of a medical center in Debrecen, Hungary, for thyroid disorders. Blood was drawn during the first 2 weeks of March 2006. Fifty patients were found to have AITDs (evidenced by autoimmune features or elevated antithyroid peroxidase or antithyroglobulin antibodies) and 42 showed no evidence of autoimmunity (non-AITDs). Gender, age and thyroid function tests and specific autoantibodies associated with AITDs were determined for each patient on the day the blood was drawn. Sera from 98 agematched matched healthy donors served as controls. The study was approved by the local ethics committee, and complied with the guidelines of the most recent Helsinki declaration (Edinburgh, 2000). Laboratory tests Antithyroid peroxidase and antithyroglobulin antibodies were tested by ELISA (Hycor Autostat II; Hycor Biomedical Inc., Garden Grove, CA, USA). Antithyroid stimulating hormone receptor antibodies were measured with a commercial ELISA kit (Medizym T.R.A.; Medipan Diagnostica, Berlin, Germany). Thyroid function tests were evaluated by routine endocrine laboratory investigations.

Figure 1 Prevalence of vitamin D deficiency among healthy subjects and patients with thyroid disease. AITD, autoimmune thyroid disease (including HT and GD); GD, Graves’ disease; HT, Hashimoto’s thyroiditis.

was performed by chi-square test and Fisher’s exact test (two-tailed) as appropriate. Continuous variables are expressed as mean6standard deviation (s.d.). The non-parametric Mann–Whitney U test was performed for comparison of levels between groups. P values ,0.05 were considered statistically significant for all tests. RESULTS Vitamin D deficiency in patients compared to healthy controls Vitamin D deficiency was diagnosed in 63% (58/92) of the patients with thyroid diseases compared to 30% (30/98) of the healthy controls (P,0.001) (Figure 1). The prevalence of vitamin D deficiency was even higher in patients with AITDs, 72% (36/50) (P,0.001), particularly in those with Hashimoto’s thyroiditis, 79% (22/28) (P,0.001), but also in Graves’ disease, 64% (14/22) (P,0.01).

Vitamin-D measurement Serum concentrations of 25-OH vitamin D in patients and controls were measured by the commercial kit LIAISON 25-OH vitamin D assay (DiaSorin, Saluggia, Italy). The quantitative determination of 25-OH vitamin D was carried out by a direct, competitive chemiluminescence immunoassay. Magnetic particles (solid phase) are coated with a specific antibody to vitamin D, and vitamin D is linked to an isoluminol derivative. During the incubation, 25-OH vitamin D is dissociated from its binding protein and competes with labeled vitamin D for binding sites on the antibody. After the incubation, the unbound material is removed with a wash cycle, the starter reagents are added, and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as relative light units and is inversely proportional to the concentration of 25-OH vitamin D present in calibrators, controls or samples. Vitamin D deficiency in our study was defined, in accordance with the manufacturer, as levels of 25-OH vitamin D below 10 ng/ml.

Vitamin D levels in all patients with thyroid disease There was no significant correlation between vitamin D deficiency and age or gender in the 92 patients referred to the endocrinology clinic (Table 1). The presence of antithyroid antibodies was significantly more common in patients with vitamin D deficiency than in those with higher vitamin D levels (43% versus 17%, respectively; P50.01). A non-significant association was also observed between vitamin D deficiency and abnormal thyroid function: patients with levels of vitamin D,10 ng/ml exhibited more abnormal thyroid function than patients with vitamin D.10 mg/ml (39% versus 18%; P50.059) (Table 1).

Statistical analysis The statistical program SPSS 13.0 (SPSS, Chicago, IL, USA) was used for all analyses. Comparison of categorical variables between groups

Vitamin D levels in AITD patients A comparison of AITD and non-AITD patients is summarized in Table 2. Fifty of the total 92 patients were diagnosed with AITDs.

Table 1 The 92 patients with thyroid disease by vitamin D level, age and gender

No. of patients Vitamin D level (ng/ml) mean6s.d. (range) Age (years) (mean6s.d.) Female gender (%) Antithyroid antibodies Abnormal thyroid function test

Vitamin D (.10 ng/ml)

Vitamin D deficiency (f10 ng/ml)

34 1766 (10–42) 46615

58 7.461 (7–10) 50616

NS

25 (73 %) 6 (17%) 6 (18%)

46 (79%) 25 (43%) 22 (39%)

NS 0.01 0.059

Abbreviation: NS, not significant; s.d., standard deviation.

Cellular & Molecular Immunology

P

,0.005


Table 2 Comparison of AITD and non-AITD patients

No. of patients Age (years) (mean6s.d.) Female gender (%) Prevalence of vitamin D deficiency (f10 ng/ml) Abnormal thyroid function test Antithyroid antibodies

Non-AITD

AITD

P

42 52616

50 45616

0.05

27 (64%) 22 (52%)

44 (88%) 36 (72%)

0.01 0.08

7 (15%)

22 (44%)

0.003

0 (0%)

31 (62%)

,0.005

Abbreviation: AITD, autoimmune thyroid disease.

Patients with AITDs were younger (mean age: 45 years versus 52 years; P50.05), and included more females (88% versus 64%; P50.01). Vitamin D deficiency was more prevalent in patients with AITDs, 72% (36/50), than in those without AITDs, 52% (22/42) (P50.08). This difference was most significant among patients with Hashimoto’s thyroiditis, 79% (P,0.05), and non-significant in those with Graves’ disease, 64% (P50.4) (Figure 1). In the AITD patients, abnormal thyroid function (non-euthyroid) was documented in 53% of the patients with low levels of vitamin D compared with only 22% of patients with levels above 10 ng/ml (P50.06). Thyroid-stimulating hormone (TSH) levels tended to have a direct relation to vitamin D status. TSH levels in Hashimoto’s thyroiditis were 4.9 mlU/l when vitamin D was ,10 ng/ml and 1.8 mlU/l when vitamin D was .10 ng/ml; and in Graves’ disease patients, 0.58 mlU/l and 3.89 mlU/l among those with vitamin D,10 ng/ml and those with vitamin D.10 ng/ml, respectively. TSH levels did not correlate with vitamin D deficiency in non-AITD patients. Thyroid hormone levels (T3 and T4) did not correlate with vitamin D levels in any of the groups. DISCUSSION Thyroid diseases are among the most common endocrine abnormalities, and AITDs are perhaps the most prevalent autoimmune diseases.11,27 The prevalence of AITDs, including Hashimoto’s thyroiditis, Graves’ disease and postpartum thyroiditis, is estimated to be as high as 5% of the general population.11 Furthermore, abnormal thyroid function varies within 7–9% in females and 1–2% in males across different populations,28 and a significant proportion of these patients will eventually be diagnosed with non-autoimmune diseases due to lack of autoantibodies detection, and/or diagnosis of toxic nodular and multinodular goiter, iodine deficiency, radiation exposure or idiopathic cases. The pathogenesis of AITDs, like other autoimmune diseases, is multifactorial, combining genetic, immune, environmental and hormonal influences such as vitamin D.29–33 Although distinct in manner, AITDs share similar autoimmune pathologies and autoantibodies; for example, both Hashimoto’s thyroiditis and Graves’ disease are characterized by a dominant T-lymphocyte infiltration of the thyroid gland. In the present study we demonstrate an increased prevalence of vitamin D deficiency among patients with AITDs, particularly Hashimoto’s thyroiditis. In addition, we report, for the first time, to the best of our knowledge, a link between vitamin D deficiency and the presence of antithyroid antibodies. An association was also found between vitamin D deficiency and TSH levels, although not significant. The lack of statistical significance may be due to the relatively small group of patients, especially after subgroup analysis. Taken together, these data suggest a pathogenic relationship between vitamin D status and AITDs.

The biologically active form of vitamin D, a secosteroid hormone essential for bone and mineral homeostasis, has been shown to have immunoregulatory and anti-inflammatory properties.34,35 Most of the known biological effects of vitamin D are mediated through the vitamin D3 receptor (VDR) 36 , and can be regulated by the vitamin D-binding protein37 and the CYP27B1 hydroxylase.38 The immune modulator properties of vitamin D are ascribed to its effect on cells of the innate and adaptive systems, including macrophages, dendritic cells, and T and B lymphocytes, all of which harbor VDRs. Dendritic cells are a primary target for the immunomodulatoric activity of vitamin D.39,40 Vitamin D has been shown to inhibit dendritic celldependent T-cell activation, and promote tolerogenic properties that favor the induction of regulatory rather that effector T cells. In addition, in vitro studies showed that activation of CD4 T cells expressing VDR by vitamin D promotes a Th2 phenotype (with IL-4 and IL-5 production) while suppressing Th1 activity (with interferon-gamma and IL-2 production).41 Currently, there is no consensus regarding the optimal serum levels of vitamin D among healthy subjects, in addition to which the clinical significance of different vitamin D levels may vary between different populations and be dependent on body mass index, gender, age and seasonal variance.42 Nevertheless, at the present time vitamin D levels above 30 ng/ml are considered sufficient and confer protection from bone disease, whereas lower levels (vitamin D insufficiency) induce elevation of parathyroid hormone and are associated with other hazardous systemic effects.43 Very low levels of this hormone, defined as ‘vitamin D deficiency’, were recently suggested to be related to even worse outcomes. Thus, we are able to estimate the impact of vitamin D deficiency on the pathogenesis of different diseases in a relative rather than quantitative manner by comparing levels of vitamin D in healthy and diseased subjects. In the current study we set vitamin D deficiency at levels below 10 ng/ml—the value that defined the lower third of a normal population examined at the same time and by the same method. Our data indicate an association between vitamin D deficiency and thyroid dysfunction, specifically when caused by an autoimmune disease. The explanation for these findings is not clear: low levels of vitamin D may be a primary phenomenon involved in the pathogenesis of the disease, or they may simply represent a consequence of the disease. Low vitamin D levels in other autoimmune diseases can be explained by malabsorption (e.g., inflammatory bowel diseases or systemic sclerosis), or by lack of sun exposure due to skin involvement or photosensitivity (e.g., SLE and dermatomyositis). Furthermore, in diseases that cause disability, such as rheumatoid arthritis and MS, reduced outdoor activity and chronic corticosteroid treatment per se might induce low vitamin D levels. However, most patients with thyroid disease generally do not suffer from significant skin disease, malabsorption or reduced outdoor activity. Another plausible explanation is that accelerated bone turnover in patients with hyperthyroidism may lead to high calcium levels and a negative feedback on parathyroid hormone and 1,25(OH)2D3 synthesis.44 Hyperthyroidism had no association in our patients with lower vitamin D levels when compared to hypothyroidism. Therefore, it seems that a primary role for vitamin D deficiency in the pathogenesis of thyroid disease should be considered. Allelic variations within the VDR gene have been implicated in mediating susceptibility to several endocrine autoimmune disorders.45,46 Recently, several genetic studies demonstrated an association between AITDs and polymorphism of the VDR, as well as other proteins and enzymes associated with vitamin D functions. Horst-Sikorska Cellular & Molecular Immunology


et al.47 linked VDR polymorphism to thyroid autoimmunity susceptibility by demonstrating a correlation between F allele carriers of the VDR-FokI polymorphism and Graves’ disease. Stefanic et al.48 reported an association between VDR-common haplotypic variants and Hashimoto’s thyroiditis. In addition, several studies demonstrated genetic polymorphism of the vitamin D-binding protein among Polish49 and Japanese50 patients with AITDs, whereas the CYP27B1 hydroxylase polymorphism was found to predispose to Hashimoto’s thyroiditis and Graves’ disease in German subjects.51 Of note, some of these associations could not be confirmed in other studies.52 The present study has several limitations, including the small number of patients, the heterogeneity of the study population, and lack of information on nutrition, social behavior (e.g., outdoor activity) and concomitant diseases. Nevertheless, it seems that the evidence links vitamin D deficiency to AITDs either via gene polymorphism or via lack of environmental uptake, supporting the notion that the effects of vitamin D on the immune system may play a role in the pathogenesis of AITDs. CONCLUSION Significantly lower levels of vitamin D were documented in patients with AITDs. Deficiency of vitamin D was linked to the presence of antithyroid antibodies and abnormal thyroid functions. Our data and those of others pointing to the involvement of vitamin D in the pathogenesis of AITDs argue for screening for vitamin D levels in patients with thyroid diseases. Moreover, as treatment with vitamin D is inexpensive and carries minimal side effects, vitamin D supplements may be recommended for AITD patients. Further research is needed to evaluate the beneficial effects of such treatment as well as the optimal doses, including a high-dose regimen of vitamin D recently found to be effective and safe, and to increase compliance in these patients.53 Additional studies are required on VDR agonists and other reagents that may target tissue-specific agents and further increase the therapeutic range.

1 2

3 4 5 6 7

8

9 10

11 12 13 14

Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483–492. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451–459. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 2009; 39: 3147–3159. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503–511. Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 2007; 22Suppl 2: V81–V85. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500–1503. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 2004; 50: 72–77. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001; 28: 2535–2539. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 114–117. Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, Marinescu LM et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One 2010; 5: e9193. Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune diseases. Autoimmunity 2010; 8: 468–476. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009; 5: 99–105 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504–513. Dahlquist G, Mustonen L. Childhood onset diabetes—time trends and climatological factors. Int J Epidemiol 1994; 23: 1234–1241.


15 The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 51– 54. 16 Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R. 1,25Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992; 41: 1491– 1495. 17 Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17: 453–456. 18 Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci 2009; 286: 104– 108. 19 Munger KL, Zhang SM, O’Reilly E, Herna´n MA, Olek MJ, Willett WC et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60–65. 20 Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990; 33: 1723–1727. 21 Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838. 22 Chen W, Lin H, Wang M. Immune intervention effects on the induction of experimental autoimmune thyroiditis. J Huazhong Univ Sci Technolog Med Sci 2002; 22: 343– 345, 354. 23 Misharin A, Hewison M, Chen CR, Lagishetty V, Aliesky HA, Mizutori Y et al. Vitamin D deficiency modulates Graves’ hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. Endocrinology 2009; 150: 1051–1060. 24 Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 2007; 6: 261–266. 25 Czernobilsky H, Scharla S, Schmidt-Gayk H, Ziegler R. Enhanced suppression of 1,25(OH)2D3 and intact parathyroid hormone in Graves’ disease as compared to toxic nodular goiter. Calcif Tissue Int 1988; 42: 5–12. 26 Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N et al. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr 2009; 102: 382–386. 27 Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008; 31: 325–330. 28 Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526–534. 29 Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases— 2008. Isr Med Assoc J 2008; 10: 13–19. 30 Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases—2008. Isr Med Assoc J 2008; 10: 3–7. 31 Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases—2008. Isr Med Assoc J 2008; 10: 8–12. 32 Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, Sherer Y et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008; 8: 112–115. 33 Gershwin ME. The mosaic of autoimmunity. Autoimmun Rev 2008; 7: 161–163. 34 van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93–101. 35 Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137–1142. 36 Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325–349. 37 Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63: 954–959. 38 Henry HL. Vitamin D hydroxylases. J Cell Biochem 1992; 49: 4–9. 39 Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411. 40 van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3. Diabetes 2002; 51: 2119–2125. 41 Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1alpha,25Dihydroxyvitamin d3 has a direct effect on naive CD41 T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980. 42 Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 2009; 29: 3713–3720. 43 Gomez-Alonso C, Naves-Diaz ML, Fernandez-Martin JL, Diaz-Lopez JB, Fernandez-Coto MT, Cannata-Andia JB. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl 2003; (85): S44–S48. 44 Iqbal AA, Burgess EH, Gallina DL, Nanes MS, Cook CB. Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 2003; 9: 517–521.

Vitamin D levels in autoimmune thyroid diseases S Kivity et al 247 45 Pani MA, Knapp M, Donner H, Braun J, Baur MP, Usadel KH et al. Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 2000; 49: 504–507. 46 Pani MA, Seissler J, Usadel KH, Badenhoop K. Vitamin D receptor genotype is associated with Addison’s disease. Eur J Endocrinol 2002; 147: 635–640. 47 Horst-Sikorska W, Ignaszak-Szczepaniak M, Marcinkowska M, Kaczmarek M, Stajgis M, Slomski R. Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves’ disease. Acta Biochim Pol 2008; 55: 371–380. 48 Stefanic M, Papic S, Suver M, Glavas-Obrovac L, Karner I. Association of vitamin D receptor gene 39-variants with Hashimoto’s thyroiditis in the Croatian population. Int J Immunogenet 2008; 35: 125–131. 49 Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves’ disease and the

50

51

52

53

vitamin D status in a Polish population study. Exp Clin Endocrinol Diabetes 2006; 114: 329–335. Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves’ disease. Thyroid 2000; 10: 475– 480. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997; 48: 312–314. Collins JE, Heward JM, Nithiyananthan R, Nejentsev S, Todd JA, Franklyn JA et al. Lack of association of the vitamin D receptor gene with Graves’ disease in UK Caucasians. Clin Endocrinol (Oxf) 2004; 60: 618–624. von Restorff C, Bischoff-Ferrari HA, Theiler R. High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. Bone 2009; 45: 747–749.
